Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07200102Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by Washington University School of Medicine. Primary endpoints: Rate of non-hematologic grade >= 3 treatment-related adverse events at 13 months and Rate of patients who received > 80% of cumulative selinexor dose at 12 months. Started Mar 2026; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07200102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200102.